BIO-TECHNE Corp - 10-Q Filing

BIO-TECHNE Corp reports Q1 fiscal 2026 results featuring restructuring costs related to global manufacturing optimization and segment performance for Protein Sciences and Diagnostics & Spatial Biology.

SEC EDGAR ·

Tickers: $TECH

Read the full article at SEC EDGAR

More Regulatory news